Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
0.8110
Nov 20 • 3:59 PM ET Dollar change-0.0290 Percentage change(-3.45%)
Aftermarket Close
0.8110
Aftermarket • 4:15 PM ET Dollar change0.0000 Percentage change(0.00%)
Index
-
Market Cap
32.52M
Enterprise Value
41.98M
Income
-15.08M
Sales
45.50M
Book/sh
0.07
Cash/sh
0.30
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
195
IPO
Jun 12, 2017
P/E
-
Forward P/E
-
PEG
-
P/S
0.71
P/B
11.81
P/C
2.72
P/FCF
-
EV/EBITDA
-
EV/Sales
0.92
Quick Ratio
1.66
Current Ratio
1.92
Debt/Eq
7.79
LT Debt/Eq
6.83
Option/Short
Yes / Yes
EPS (ttm)
-0.35
EPS next Y
-0.20
EPS next Q
-0.06
EPS this Y
12.97%
EPS next Y
38.51%
EPS next 5Y
34.81%
EPS past 3/5Y
37.45% 36.74%
Sales past 3/5Y
38.05% 40.10%
EPS Y/Y TTM
-22.32%
Sales Y/Y TTM
9.27%
EPS Q/Q
-11.85%
Sales Q/Q
22.20%
Insider Own
10.45%
Insider Trans
-0.35%
Inst Own
32.41%
Inst Trans
-4.56%
ROA
-44.42%
ROE
-173.54%
ROIC
-70.01%
Gross Margin
70.15%
Oper. Margin
-21.78%
Profit Margin
-33.14%
SMA20
-30.03%
SMA50
-38.60%
SMA200
-25.99%
Trades
Shs Outstand
40.05M
Shs Float
35.91M
52W High
1.88 -56.98%
52W Low
0.61 34.05%
Volatility
12.13% 9.47%
ATR (14)
0.11
RSI (14)
28.57
Beta
1.82
Rel Volume
1.06
Avg Volume
355.92K
Volume
378,122
Perf Week
-34.07%
Perf Month
-33.52%
Perf Quarter
-41.65%
Perf Half Y
-22.02%
Perf YTD
-10.88%
Perf Year
12.64%
Perf 3Y
-73.50%
Perf 5Y
-90.59%
Perf 10Y
-
Prev Close
0.84
Price
0.81
Change %
-3.45%
Consensus
Strong Buy
Avg. Price Target
$4.64
Implied Upside
+472.1%
Analysts5incl. previous ratings
Rating Distribution5 Buy · 0 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Jul 31, 2024Initiated
CCraig Hallum
Buy$7+763.1%
May 20, 2024Initiated
LLake Street
Buy$7+763.1%
Dec 15, 2023Initiated
HH.C. Wainwright
Buy$6.50+701.5%
Nov 11, 2020Upgrade
RROTH Capital
Neutral → Buy$5 → $7+763.1%
May 27, 2020Initiated
DDougherty & Company
Buy$8.50+948.1%
Oct 02, 2017Initiated
HH.C. Wainwright
Buy$12+1,379.7%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
David HenryOfficerOct 12 '26Proposed Sale1.373,1334,292Oct 13 09:27 AM
Kovelman HarryChief Medical OfficerSep 11 '26Sale1.2715,48819,68490,245Sep 14 04:30 PM
HARRY KOVELMANOfficerSep 11 '26Proposed Sale1.2715,84420,136Sep 11 04:37 PM
Morris Milton MayoDirectorSep 02 '26Sale1.4115,00021,150208,391Sep 04 04:30 PM
Morris Milton MayoDirectorSep 02 '26Proposed Sale1.4115,00021,150Sep 02 03:06 PM
Kovelman HarryChief Medical OfficerAug 20 '26Sale1.7317,25029,896105,983Aug 21 06:17 PM
HARRY KOVELMANOfficerAug 20 '26Proposed Sale1.7317,50030,329Aug 20 04:04 PM
David HenryOfficerJul 13 '26Proposed Sale1.095,1665,631Jul 13 04:29 PM
Harry KovelmanOfficerJun 12 '26Proposed Sale1.2010,44212,530Jun 12 04:17 PM
Micah MitchellOfficerJun 12 '26Proposed Sale1.209,06110,873Jun 12 04:16 PM
KIRK THOMAS FDirectorJun 05 '26Buy1.2740,00250,803693,865Jun 09 04:07 PM
Harry KovelmanOfficerJun 08 '26Proposed Sale1.337,63510,155Jun 08 04:12 PM
Micah MitchellOfficerJun 08 '26Proposed Sale1.336,5298,684Jun 08 04:10 PM
KIRK THOMAS FDirectorMay 28 '26Buy0.9925,00024,825653,863Jun 01 08:23 AM
Kovelman HarryChief Medical OfficerMay 27 '26Sale1.0020,46420,505120,154May 28 09:53 PM
Kovelman HarryChief Medical OfficerMay 28 '26Sale1.0211,53611,734108,618May 28 09:53 PM
HARRY KOVELMANOfficerMay 28 '26Proposed Sale1.0211,53611,734May 28 05:01 PM
HARRY KOVELMANOfficerMay 27 '26Proposed Sale1.0020,46420,468May 27 06:36 PM
KIRK THOMAS FDirectorMay 18 '26Buy0.9143,40139,495628,863May 18 08:20 PM
KIRK THOMAS FDirectorMay 15 '26Buy0.9131,60528,748585,462May 18 08:20 PM
Manko Joseph M. Jr.DirectorMay 14 '26Buy0.86170,830146,9482,279,408May 18 04:59 PM
Manko Joseph M. Jr.DirectorMay 15 '26Buy0.8930,36726,9602,309,775May 18 04:59 PM
MICAH MITCHELLOfficerMay 14 '26Proposed Sale0.8690,23177,689May 14 06:31 PM
David HenryOfficerApr 13 '26Proposed Sale0.713,9532,807Apr 13 04:21 PM
Getz Heather CDirectorMar 16 '26Buy0.7020,00013,972131,754Mar 17 05:39 PM
KIRK THOMAS FDirectorMar 13 '26Buy0.7172,00051,113553,857Mar 16 06:08 PM
Getz Heather CDirectorMar 12 '26Buy0.7370,00050,960111,754Mar 12 05:18 PM
KIRK THOMAS FDirectorNov 21 '25Buy0.722,5351,825481,857Nov 24 04:04 PM
Myomo, Inc. is a wearable medical robotics company, which engages in the business of developing, designing, and producing myoelectric orthotics for people with neuromuscular disorders. It is also involved in selling products through various other sales channels including through orthotics and prosthetics providers, veterans' administration, and to distributors in certain accounts and geographic markets. The company was founded by Stephen Kelly, John McBean, Mira Sahney, and Kailas N. Narendran on September 1, 2004 and is headquartered in Burlington, MA.
PresidentMr. Paul R. Gudonis
Chief Financial OfficerMr. David A. Henry
Chief Medical OfficerDr. Harry Kovelman M.D.
Senior Director of Global OperationsMr. Colin Anderson
Vice President of Human ResourcesMs. Galina Shtivelman